FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2790647466> ?p ?o ?g. }

• W2790647466 endingPage "127" @default.
• W2790647466 startingPage "119" @default.
• W2790647466 abstract "This randomized phase III study was designed to compare the efficacy and safety of irinote-can plus cisplatin (IP) over etoposide plus cisplatin (EP) in Korean patients with extensive-disease small-cell lung cancer (SCLC).Patients were randomly assigned to receive IP, composed of irinotecan 65 mg/m2 intravenously on days 1 and 8+cisplatin 70 mg/m2 intravenously on day 1 every 3 weeks, or EP, composed of etoposide 100 mg/m2 intravenously on days 1, 2, 3+cisplatin 70 mg/m2 intravenously on day 1, every 3 weeks for a maximum of six cycles, until disease progression, or until unacceptable toxicity occurred. The primary endpoint was overall survival.A total of 362 patients were randomized to IP (n=173) and EP (n=189) arms. There were no significant differences between IP and EP arms for the median overall survival (10.9 months vs. 10.3 months, p=0.120) and the median progression-free survival (6.5 months vs. 5.8 months, p=0.115). However, there was a significant difference in response rate (62.4% vs. 48.2%, p=0.006). The pre-planned subgroup analyses showed that IP was associated with longer overall survival in male (11.3 months vs. 10.1 months, p=0.036), < 65 years old (12.7 months vs. 11.3 months, p=0.024), and Eastern Cooperative Oncology Group performance status 0/1 (12.4 months vs. 10.9 months, p=0.040) patient groups. The severity of treatment-related adverse events such as grade 3/4 anemia, nausea and diarrhea was more frequent in patients treated with IP.The IP chemotherapy did not significantly improve the survival compared with EP chemotherapy in Korean patients with extensive-disease SCLC." @default.
• W2790647466 created "2018-03-29" @default.
• W2790647466 creator A5005358526 @default.
• W2790647466 creator A5005962138 @default.
• W2790647466 creator A5011582408 @default.
• W2790647466 creator A5016978421 @default.
• W2790647466 creator A5020591861 @default.
• W2790647466 creator A5020992348 @default.
• W2790647466 creator A5024891671 @default.
• W2790647466 creator A5030107272 @default.
• W2790647466 creator A5041556537 @default.
• W2790647466 creator A5045922502 @default.
• W2790647466 creator A5048145361 @default.
• W2790647466 creator A5057550966 @default.
• W2790647466 creator A5059915781 @default.
• W2790647466 creator A5065376753 @default.
• W2790647466 creator A5067307453 @default.
• W2790647466 creator A5068310127 @default.
• W2790647466 creator A5074980266 @default.
• W2790647466 creator A5090737086 @default.
• W2790647466 date "2019-01-15" @default.
• W2790647466 modified "2023-10-10" @default.
• W2790647466 title "Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer" @default.
• W2790647466 cites W1850736485 @default.
• W2790647466 cites W1918894023 @default.
• W2790647466 cites W1952431753 @default.
• W2790647466 cites W1959962586 @default.
• W2790647466 cites W1976228473 @default.
• W2790647466 cites W2009608310 @default.
• W2790647466 cites W2032584323 @default.
• W2790647466 cites W2073683299 @default.
• W2790647466 cites W2078359995 @default.
• W2790647466 cites W2079216966 @default.
• W2790647466 cites W2106787323 @default.
• W2790647466 cites W2117150909 @default.
• W2790647466 cites W2119388991 @default.
• W2790647466 cites W2123767004 @default.
• W2790647466 cites W2129992678 @default.
• W2790647466 cites W2139248078 @default.
• W2790647466 cites W2159392804 @default.
• W2790647466 cites W2165254830 @default.
• W2790647466 cites W2166418266 @default.
• W2790647466 cites W2169848988 @default.
• W2790647466 cites W2170260373 @default.
• W2790647466 cites W2917116917 @default.
• W2790647466 doi "https://doi.org/10.4143/crt.2018.019" @default.
• W2790647466 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6334001" @default.
• W2790647466 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29529858" @default.
• W2790647466 hasPublicationYear "2019" @default.
• W2790647466 type Work @default.
• W2790647466 sameAs 2790647466 @default.
• W2790647466 citedByCount "23" @default.
• W2790647466 countsByYear W27906474662018 @default.
• W2790647466 countsByYear W27906474662019 @default.
• W2790647466 countsByYear W27906474662020 @default.
• W2790647466 countsByYear W27906474662021 @default.
• W2790647466 countsByYear W27906474662022 @default.
• W2790647466 countsByYear W27906474662023 @default.
• W2790647466 crossrefType "journal-article" @default.
• W2790647466 hasAuthorship W2790647466A5005358526 @default.
• W2790647466 hasAuthorship W2790647466A5005962138 @default.
• W2790647466 hasAuthorship W2790647466A5011582408 @default.
• W2790647466 hasAuthorship W2790647466A5016978421 @default.
• W2790647466 hasAuthorship W2790647466A5020591861 @default.
• W2790647466 hasAuthorship W2790647466A5020992348 @default.
• W2790647466 hasAuthorship W2790647466A5024891671 @default.
• W2790647466 hasAuthorship W2790647466A5030107272 @default.
• W2790647466 hasAuthorship W2790647466A5041556537 @default.
• W2790647466 hasAuthorship W2790647466A5045922502 @default.
• W2790647466 hasAuthorship W2790647466A5048145361 @default.
• W2790647466 hasAuthorship W2790647466A5057550966 @default.
• W2790647466 hasAuthorship W2790647466A5059915781 @default.
• W2790647466 hasAuthorship W2790647466A5065376753 @default.
• W2790647466 hasAuthorship W2790647466A5067307453 @default.
• W2790647466 hasAuthorship W2790647466A5068310127 @default.
• W2790647466 hasAuthorship W2790647466A5074980266 @default.
• W2790647466 hasAuthorship W2790647466A5090737086 @default.
• W2790647466 hasBestOaLocation W27906474661 @default.
• W2790647466 hasConcept C121608353 @default.
• W2790647466 hasConcept C126322002 @default.
• W2790647466 hasConcept C141071460 @default.
• W2790647466 hasConcept C168563851 @default.
• W2790647466 hasConcept C197934379 @default.
• W2790647466 hasConcept C203092338 @default.
• W2790647466 hasConcept C2776256026 @default.
• W2790647466 hasConcept C2776694085 @default.
• W2790647466 hasConcept C2778119113 @default.
• W2790647466 hasConcept C2778239845 @default.
• W2790647466 hasConcept C2780259306 @default.
• W2790647466 hasConcept C31760486 @default.
• W2790647466 hasConcept C526805850 @default.
• W2790647466 hasConcept C71924100 @default.
• W2790647466 hasConcept C90924648 @default.
• W2790647466 hasConceptScore W2790647466C121608353 @default.
• W2790647466 hasConceptScore W2790647466C126322002 @default.
• W2790647466 hasConceptScore W2790647466C141071460 @default.
• W2790647466 hasConceptScore W2790647466C168563851 @default.
• W2790647466 hasConceptScore W2790647466C197934379 @default.

• next